Moderna shares fall despite promising data from cancer vaccine trial

Moderna’s mRNA vaccine, when combined with Merck’s blockbuster drug Keytruda, showed promise in treating melanoma, a kind of skin cancer.

Previous post Nikki Haley gets early support from wealthy donors while some remain on the sidelines
Next post Homebuilder sentiment rises in April, as builders grab near-record share of the market